Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying antirheumatic drugs.

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months ...

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug ...

Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales, Australia (“Court”) has today made orders approving the scheme of arrangement ...

A new analysis shows how Bruton tyrosine kinase (BTK) inhibitors affect full-length BTK conformation by investigating the ...

This summary highlights only some of the key features and terms of the actual license. It is not a license and has no legal value. Carefully review the actual license before using these materials.

Those labels help users choose what they want to consume on the site, and also for brands to have more control over where their ads appear, Twitch said. “Our goal isn’t to stifle conversation ...

It was previously reported that the site had been taken down on December 5, “at the request of Spotify’s legal team”. However, a spokesperson for Spotify has since claimed to NME that the ...

NEU-111 is a potent and highly selective oral allosteric inhibitor of tyrosine kinase 2 (TYK2), a JAK family protein that plays a key role in pathological immune signaling. “We are thrilled to ...

Photo by Rick Kern/Getty Images for Vox Media The Verge, a tech news site founded in 2011 and owned by Vox Media, erected a paywall for the first time on Tuesday in an announcement from editor-in ...

It will involve both single and multiple-ascending doses being given to healthy volunteers. SUDO-550 is an allosteric tyrosine kinase 2 (TYK2) inhibitor that is orally administered and designed to be ...

“This is the second allosteric TYK2 inhibitor we have advanced into the clinic this year, after SUDO-286 which is progressing in two Phase 1 trials as a topical treatment for psoriasis.